Cidara Therapeutics Inc. (CDTX): A Technical View

As of Thursday close, Cidara Therapeutics Inc.’s (NASDAQ:CDTX) stock was down -$0.13, moving down -22.66 percent to $0.46. The average number of shares traded per day over the past five days has been 425,780 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.3164 fall in that time frame. In the last twenty days, the average volume was 262,985, while in the previous 50 days, it was 259,930.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Since last month, CDTX stock retreated -39.36%. Shares of the company fell to $0.4121 on 05/12/22, the lowest level in the past month. A 52-week high of $2.39 was reached on 01/03/22 after having rallying from a 52-week low of $0.57. Since the beginning of this year, CDTX’s stock price has dropped by -63.78% or -$0.8100, and marked a new high 1 time. However, the stock has declined by -80.75% since its 52-week high.

Cidara Therapeutics Inc. (CDTX) last reported insider trading activity 53 days ago on Mar 21. Johnson Brady, the Vice President, Finance of the company, disposed of 654 shares for $0.81 on Mar 21. It resulted in a $530 divestment by the insider. Johnson Brady sold 945 shares at an average price of $0.71 on Mar 11. The insider now owns 50,020 shares following the transaction. On Jan 05, Chief Scientific Officer Tari Leslie sold 1,252 shares at $1.25 apiece. The transaction was valued at $1,565.

Valuation Metrics

The stock’s beta is 1.34. Besides these, the trailing price-to-sales (P/S) ratio of 0.64, the price-to-book (PB) ratio of 1.39.

Financial Health

In the three months ended September 29, Cidara Therapeutics Inc.’s quick ratio stood at 2.10, while its current ratio was 2.10, showing that the company is able to pay off its debt. In the year ended September 29, operating margins totaled -85.20%. Based on annual data, CDTX earned $91.83 million in gross profit and brought in $49.57 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -174.60%. Return on equity (ROE) for the past 12 months was -445.90%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected Cidara Therapeutics Inc. to report -$0.36 quarterly earnings, the actual figure was -$0.37 per share, beating the consensus estimate by -2.80%. During the quarter, the company generated -$17.96 million in EBITDA. The liabilities of Cidara Therapeutics Inc. were 50.34 million at the end of its most recent quarter ended September 29, and its total debt was $6.35 million. The value of shareholders’ equity is $69.05 million.

Technical Picture

This quick technical analysis looks at Cidara Therapeutics Inc.’s (CDTX) price momentum. With a historical volatility rate of 143.70%, the RSI 9-day stood at 14.82% on 12 May.

With respect to its five-day moving average, the current Cidara Therapeutics Inc. price is down by -40.75% percent or -$0.3164. At present, CDTX shares trade -42.49% below its 20-day simple moving average and -68.28% percent below its 100-day simple moving average. However, the stock is currently trading approximately -33.33% below its SMA50 and -69.74% below its SMA200.

Stochastic coefficient K was 10.85% and Stochastic coefficient D was 20.56%, while ATR was 0.0874. Given the Stochastic reading of 11.95% for the 14-day period, the RSI (14) reading has been calculated as 21.93%. As of today, the MACD Oscillator reading stands at -0.1075, while the 14-day reading stands at -0.1249.

Analyst Ratings

Cidara Therapeutics Inc. (CDTX) has been rated Buy by analysts. According to 0 brokerage firms, CDTX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Cidara Therapeutics Inc. stock as buy, with 6 recommending it as overweight.

With a median target price of $6.00, the current consensus forecast for the stock is $3.00 – $8.00. Based on these forecasts, analysts predict Cidara Therapeutics Inc. (CDTX) will achieve an average price target of $5.67.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles